Subgroups | Persons at risk | No. of events | Hazard ratio (95% CI) per 1-SD increment in log-transformed (log10) urinary NT-proBNPa | P for heterogeneity |
---|---|---|---|---|
Overall | 3055 | 169 | 1.20 (1.07–1.35) | |
Age | ||||
40–64 years | 1691 | 32 | 1.21 (0.75–1.96) | 0.44 |
≥ 65 years | 1364 | 137 | 1.25 (1.11–1.41) | |
Sex | ||||
Men | 1286 | 92 | 1.21 (1.03–1.41) | 0.48 |
Women | 1769 | 77 | 1.30 (1.08–1.57) | |
Hypertension | ||||
No | 1612 | 47 | 1.39 (1.06–1.81) | 0.11 |
Yes | 1443 | 122 | 1.17 (1.02–1.33) | |
Use of antihypertensive agents | ||||
No | 2161 | 89 | 1.30 (1.09–1.56) | 0.08 |
Yes | 894 | 80 | 1.16 (0.98–1.37) | |
Diabetes | ||||
No | 2597 | 122 | 1.26 (1.11–1.43) | 0.24 |
Yes | 458 | 47 | 0.96 (0.71–1.29) | |
Hypercholesterolemia | ||||
No | 1610 | 79 | 1.20 (1.03–1.40) | 0.54 |
Yes | 1445 | 90 | 1.13 (0.95–1.35) | |
Use of lipid-lowering drugs | ||||
No | 2630 | 130 | 1.19 (1.03–1.37) | 0.65 |
Yes | 425 | 39 | 1.34 (1.07–1.67) | |
Body mass index (kg/m2) | ||||
< 25 | 2268 | 117 | 1.25 (1.09–1.42) | 0.38 |
≥ 25 | 787 | 52 | 1.18 (0.93–1.51) | |
eGFR level (mL/min/1.73 m2) | ||||
≥ 60 | 2742 | 130 | 1.30 (1.10–1.53) | 0.07 |
< 60 | 313 | 39 | 1.18 (1.00–1.39) |